Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05916248 Recruiting - Clinical trials for Advanced Solid Tumor

Personalized Tumor Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

Start date: May 18, 2023
Phase: Phase 1
Study type: Interventional

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of advanced solid tumors. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

NCT ID: NCT05915481 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors

SCARCE
Start date: June 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors. The main questions it aims to answer are: - How safe is this regimen of SBRT combined with Cadonilimab for advanced refractory malignant solid tumors? - How effective is this regimen of SBRT combined with Cadonilimab for advanced refractory malignant solid tumors? Participants will receive SBRT combined with Cadonilimab until disease progression or intolerable toxicities or death.

NCT ID: NCT05911464 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.

NCT ID: NCT05909241 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of BA1202 in Patients With Advanced Solid Tumors

Start date: August 16, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single-arm phase I study in patients with advanced solid tumors which consists of a dose escalation part (Part A) and a dose extension part (Part B). Part A aims to evaluate the safety and tolerability of BA1202, and determine the MTD. Part B will also evaluate the preliminary efficacy of BA1202.

NCT ID: NCT05908773 Completed - Clinical trials for Advanced Solid Tumor

A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors

Start date: April 4, 2023
Phase: Early Phase 1
Study type: Interventional

This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with advanced solid tumors and radiographically confirmed metastases. The study will evaluate delivery of TTX-MC138-NODAGA-Cu64 radiographically and establish the PK and biodistribution of TTX-MC138-NODAGA-Cu64 as determined by PET-MRI. The study consists of 3 parts: a screening period, dosing period, and follow-up period. The estimated total duration of the study is approximately 46 days. Approximately 12 subjects with advanced metastatic solid tumors will be enrolled at 1 single site.

NCT ID: NCT05906862 Recruiting - Clinical trials for Advanced Solid Tumor

AMT-253 in Patients With Selected Advanced Solid Tumours

Start date: November 6, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors

NCT ID: NCT05902988 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Start date: October 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

NCT ID: NCT05901285 Recruiting - Clinical trials for Advanced Solid Tumor

Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors

Start date: November 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) in patients with advanced solid tumors. VAX014 is a targeted oncolytic agent designed to kill tumor cells following intratumoral injection into advanced solid tumors.

NCT ID: NCT05898399 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Start date: June 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib.

NCT ID: NCT05895825 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of EOC237 in Patients With Advanced Solid Tumor

Start date: July 26, 2023
Phase: Phase 1
Study type: Interventional

This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.